14:08:41 EDT Tue 27 Sep 2022
Enter Symbol
or Name
USA
CA



News for U:MYOV from 2021-09-28 to 2022-09-27 - 41 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2022-09-16 16:30U:MYOVNews ReleaseMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
2022-09-16 10:37U:MYOVNews ReleaseMyovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
2022-09-02 06:45U:MYOVNews ReleaseMyovant Sciences to Participate at Upcoming Investor Conferences
2022-08-16 16:30U:MYOVNews ReleaseMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
2022-08-05 20:50U:MYOVNews ReleaseMyovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE(TM), a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
2022-07-27 16:05U:MYOVNews ReleaseMyovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
2022-07-18 16:30U:MYOVNews ReleaseMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
2022-07-13 06:45U:MYOVNews ReleaseMyovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
2022-06-27 08:00U:MYOVNews ReleaseEnzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
2022-06-17 06:45U:MYOVNews ReleaseMyovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
2022-06-16 16:35U:MYOVNews ReleaseMyovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
2022-06-03 06:50U:MYOVNews ReleaseMyovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-02 06:50U:MYOVNews ReleaseMyovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE(TM)
2022-05-16 09:00U:MYOVNews ReleaseSpirovant Launches State-of-the-Art Laboratory and Headquarters
2022-05-10 08:00U:MYOVNews ReleasePhathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
2022-05-10 06:55U:MYOVNews ReleaseMyovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
2022-05-09 06:30U:MYOVNews ReleaseMyovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX(TM) for Advanced Hormone-Sensitive Prostate Cancer in Europe
2022-05-06 08:00U:MYOVNews ReleaseALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION
2022-05-06 06:45U:MYOVNews ReleaseMyovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE(TM) for the Management of Moderate to Severe Pain Associated With Endometriosis
2022-05-02 08:00U:MYOVNews ReleaseALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
2022-04-29 19:10U:MYOVNews ReleaseMyovant Sciences Announces European Commission Approval for ORGOVYX(TM) (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
2022-04-26 08:30U:MYOVNews ReleaseMyovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
2022-04-26 08:00U:MYOVNews ReleasePhathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
2022-04-21 08:00U:MYOVNews ReleaseEnzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
2022-04-12 00:00U:MYOVNews ReleaseMyovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE(TM) for the Management of Moderate to Severe Pain Associated with Endometriosis
2022-02-25 09:00U:MYOVNews ReleaseMyovant Sciences Receives Positive CHMP Opinion for ORGOVYX(TM) (relugolix) for the Treatment of Advanced Prostate Cancer
2022-02-10 09:00U:MYOVNews ReleaseSumitomo Dainippon Pharma and Sumitovant Biopharma Initiate Phase 1 Study on New Drug Candidate for Carbapenem-Resistant Bacterial Infections
2022-02-07 08:30U:MYOVNews ReleaseMyovant Sciences to Present at Upcoming Investor Conferences
2022-01-26 08:00U:MYOVNews ReleaseEnzyvant Appoints Johanna Rossell as Chief Commercial Officer
2022-01-26 06:55U:MYOVNews ReleaseMyovant Sciences Announces Financial Results for Third Quarter of Fiscal Year 2021 and Corporate Updates
2022-01-12 08:30U:MYOVNews ReleaseMyovant Sciences to Host Third Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on January 26, 2022
2022-01-10 06:55U:MYOVNews ReleaseMyovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
2022-01-03 08:30U:MYOVNews ReleaseMyovant Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-10 10:26U:MYOVNews ReleaseSumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
2021-11-23 08:30U:MYOVNews ReleaseMyovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference
2021-11-08 06:00U:MYOVNews ReleaseNancy Valente, M.D. Joins Myovant Sciences ’ Board of Directors
2021-10-28 12:03U:MYOVNews ReleaseSpirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference
2021-10-26 06:55U:MYOVNews ReleaseMyovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates
2021-10-19 06:58U:MYOVNews ReleaseMyovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress
2021-10-12 08:30U:MYOVNews ReleaseMyovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021
2021-10-08 20:10U:MYOVNews ReleaseEnzyvant Receives FDA Approval for RETHYMIC ® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia